NJ-ALPHAWAVE-SEMI
30.1.2024 17:31:33 CET | Business Wire | Press release
Nubis Communications, Inc., provider of low-latency high-density optical inter-connect (HDI/O), and Alphawave Semi (LN: AWE), a global leader in high-speed connectivity and compute silicon for the world’s technology infrastructure, today announced their upcoming demonstration of PCI Express 6.0 technology driving over an optical link at 64GT/s per lane. Data Center providers are exploring the use of PCIe over Optics to greatly expand the reach and flexibility of the interconnect for memory, CPUs, GPUs, and custom silicon accelerators to enable more scalable and energy-efficient clusters for Artificial Intelligence and Machine Learning (ML/AI) architectures.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240130752202/en/
Nubis Communications and Alphawave Semi will be showing a live demonstration in the Tektronix booth at DesignCon, the leading conference for advanced chip, board, and system design technologies. An Alphawave Semi PCIe Subsystem with PiCORE Controller IP and PipeCORE PHY will directly drive and receive PCIe 6.0 traffic through a Nubis XT1600 linear optical engine to demonstrate a PCIe 6.0 optical link at 64GT/s per fiber, with optical output waveform measured on a Tektronix sampling scope with a high-speed optical probe.
Optical transmission technology can be leveraged to greatly extend link distances at the same bandwidths compared with copper cables, supporting the larger cluster sizes needed to support ever-larger AI/ML servers distributed over multiple nodes, and enabling innovation in new disaggregated network architectures. The Nubis XT1600 optical engine supports up to 16 lanes of high-density PCIe Gen 6.0 or 100 Gbps/lane Ethernet optical connectivity without incorporating retimers.
“Our high level of integration with 16 lanes full-duplex in a single low-power, low-latency optical engine is a great match to the maximum bandwidth of PCIe x16 for next-generation compute and storage deployments,” said Scott Schube, VP of Marketing at Nubis Communications. “Our demonstration of the Nubis XT1600 linear optical engine and Alphawave Semi’s PCIe 6.0 Controller and PHY IP showcases the viability of a PCIe® 6.0 x8 link over optical fiber at 64 GT/s.”
“AI applications are reshaping data center networks, with hyperscalers deploying increasingly large clusters of disaggregated servers distributed over longer distances. This shift has generated heightened interest in PCIe over Optics among several of our customers,” said Tony Chan Carusone, CTO at Alphawave Semi. “Through our collaboration with Nubis, we’re pleased to demonstrate how we’re leveraging Alphawave Semi’s leadership in connectivity IP and silicon to enable PCIe optical connectivity solutions that accelerate high-performance AI computing and data infrastructure.”
Availability
The Nubis XT1600™ linear optical engine is available now for sampling, please contact via nubis-inc.com.
More on Alphawave Semi’s PCIe Portfolio: Alphawave Semi’s PCI-Express Solution
About Nubis Communications
Nubis innovates across photonics, electronics, packaging, and manufacturing to create optics with significantly better scalability, density, and power efficiency than existing solutions, breaking the I/O wall in data centers and enabling more advanced computing, AI, and machine learning. For more information visit https://www.nubis-inc.com.
XT-1600, HDI/O, and the Nubis Cloud Logo are trademarks of Nubis Communications.
About Alphawave Semi
Alphawave Semi is a global leader in high-speed connectivity and compute silicon for the world’s technology infrastructure. Faced with the exponential growth of data, Alphawave Semi’s technology services a critical need: enabling data to travel faster, more reliably and with higher performance at lower power. We are a vertically integrated semiconductor company, and our IP, custom silicon, and connectivity products are deployed by global tier-one customers in data centers, compute, networking, AI, 5G, autonomous vehicles, and storage. Founded in 2017 by an expert technical team with a proven track record in licensing semiconductor IP, our mission is to accelerate the critical data infrastructure at the heart of our digital world. To find out more about Alphawave Semi, visit: awavesemi.com.
Alphawave Semi and the Alphawave Semi logo are trademarks of Alphawave IP Group plc. All rights reserved.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130752202/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom